TP53 and myelodysplastic syndrome: In addition, biallelic TP53 alterations, defined as multiple mutations or mutation with concurrent deletion of the other allele, have a major influence on classification of myelodysplastic syndrome in the 5th edition of the World Health Organization (WHO) classification of hematolymphoid tumors and International Consensus Classification (ICC) of Myeloid Neoplasms, but the allelic state of TP53 does not impact the classification of AML [3,4].